HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients.

AbstractEleven patients with severe, chloroquine-resistant chronic cutaneous lupus erythematosus were treated with oral thalidomide. Seven patients responded with a complete remission, and two patients' conditions improved significantly. One patient did not respond well to therapy and another patient had to be withdrawn from the treatment trial because of side effects. Six patients, who relapsed after discontinuing thalidomide treatment, were re-treated with maintenance drug dosages and achieved good results with no further relapses or exacerbations. In all subjects the side effects from the thalidomide were minor and reversible.
AuthorsM F Hasper
JournalArchives of dermatology (Arch Dermatol) Vol. 119 Issue 10 Pg. 812-5 (Oct 1983) ISSN: 0003-987X [Print] UNITED STATES
PMID6614949 (Publication Type: Journal Article)
Chemical References
  • Thalidomide
Topics
  • Adult
  • Aged
  • Drug Administration Schedule
  • Female
  • Humans
  • Lupus Erythematosus, Discoid (drug therapy)
  • Male
  • Middle Aged
  • Recurrence
  • Thalidomide (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD